AI Article Synopsis
- Good glycaemic control in diabetes is limited by fear of insulin injections, prompting interest in inhaled insulin as a potential alternative for type 2 diabetes patients.
- Phase III clinical studies indicate that inhaled insulin is as effective as traditional subcutaneous insulin for blood sugar management, but no comparisons with short-acting insulin analogues have been made.
- Further long-term safety studies and cost-effectiveness evaluations of inhaled insulin are necessary, and it should be used selectively among patients.
Article Abstract
Good glycaemic control of diabetes mellitus is still hampered by the fear of insulin injections. Particularly in patients with type 2 diabetes, inhaled insulin as a novel therapeutic option for glycaemic control could be an alternative to subcutaneous insulin. Phase III clinical studies have shown glycaemic equivalence between inhaled insulin and conventional subcutaneous insulin. However, no study comparing inhaled insulin with short-acting insulin analogues has yet been published. Thus, methodological problems preclude conclusive remarks concerning quality-of-life issues. Inhaled insulin should be reserved for selected patient groups only. Lengthier studies to evaluate the long-term (pulmonary) safety of inhaled insulin and a cost-effectiveness study are needed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!